Novellus
Cambridge
About Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $58.0M
- Funding stage: M&A
- Last round: Series C (Sep 2020)
- Website: novellustx.com
- Phone: 617-285-2632
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/novellus-29178 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.